NYSE$AMPE
Ampio Pharmaceuticals Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Ampio reported financial results for Q4 2020 and provided a business update.
Ampio Pharmaceuticals reported its annual financial results for the year ended December 31, 2020. The company's cash and cash equivalents totaled $17.3 million, and research and development expenditures were $9.2 million.
- FDA recommended a randomized, double-blinded, placebo-controlled Phase II trial for IV and Inhaled Ampion.
- Proposal submitted to FDA regarding Osteoarthritis of the Knee (OAK) Phase III clinical trial.
- Cash and cash equivalents totaled $17.3 million at December 31, 2020.
- Research and development expenditures were $9.2 million for the year ended December 31, 2020.
Headline financials
Revenue & EPS history
Ampio · Revenue · Quarterly
$0
Forward guidance
Ampio expects to have sufficient cash to fund operations through the first quarter of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-0.4%
Avg return
Earnings day
-3.9%
Avg return
5 days after
-17.0%
Avg return
30 days after
31%
10 / 32 earnings
Positive
+32.5%
Q1 2011
Best reaction
-20.0%
Q4 2010
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2023 | +13.4% | -2.2% | -60.4% | |
| Q3 2023 | +6.2% | +0.1% | -21.1% | |
| Q2 2023 | +4.8% | -0.3% | +3.0% | |
| Q1 2023 | -8.3% | -8.9% | -3.5% | |
| Q4 2022 | +4.0% | -6.8% | -16.9% | |
| Q3 2022 | -18.9% | +8.1% | -25.8% | |
| Q3 2024 | -10.3% | -31.0% | -46.0% | |
| Q2 2022 | -9.1% | -4.5% | -15.9% | |
| Q1 2022 | +0.0% | -1.7% | -50.0% | |
| Q4 2021 | -8.0% | -7.7% | -57.2% | |
| Q3 2021 | -14.7% | -19.6% | -39.2% | |
| Q2 2021 | +9.8% | +13.6% | +28.8% | |
| Q1 2021 | +12.8% | +7.9% | -99.6% | |
| Q4 2020 | -5.5% | -10.9% | +12.1% | |
| Q3 2020 | +1.2% | -6.4% | +27.4% | |
| Q2 2020 | -1.9% | +0.9% | -30.4% | |
| Q1 2020 | +23.3% | +14.6% | +42.9% | |
| Q3 2019 | -7.7% | -7.3% | +7.1% | |
| Q1 2019 | +0.0% | -5.8% | +1.4% | |
| Q4 2018 | -8.8% | -16.2% | -24.7% | |
| Q3 2018 | -1.7% | -1.5% | -31.5% | |
| Q2 2018 | -2.1% | +0.6% | +26.3% | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q3 2012 | -4.7% | — | — | |
| Q1 2012 | -0.4% | — | — | |
| Q4 2011 | -2.6% | — | — | |
| Q3 2011 | -4.9% | — | — | |
| Q2 2011 | -1.3% | — | — | |
| Q1 2011 | +32.5% | — | — | |
| Q4 2010 | -20.0% | — | — | |
| Q3 2010 | -3.3% | — | — | |
| Q2 2010 | +27.3% | — | — | |
| Q1 2010 | -14.3% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro